Title :

Predictive biomarkers for immune checkpoint inhibitor response in urothelial cancer

Author(s) :

Parent, Pauline [Auteur correspondant]
Service d'oncologie médicale (CHRU Lille)
Marcq, Gautier [Auteur]
Service d'Urologie, andrologie et transplantation rénale [CHRU Lille]
Adeleke, Sola [Auteur]
Guy's and St Thomas' NHS Foundation Trust
King‘s College London
Hétérogénéité, Plasticité et Résistance aux Thérapies des Cancers = Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Turpin, Anthony [Auteur]
Service d'oncologie médicale (CHRU Lille)
Hétérogénéité, Plasticité et Résistance aux Thérapies des Cancers = Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Boussios, Stergios [Auteur]
Guy's and St Thomas' NHS Foundation Trust
Medway NHS Foundation Trust
AELIA Organization, [Thessalonique, Grèce]
Rassy, Elie [Auteur]
Département de médecine oncologique [Gustave Roussy]
Penel, Nicolas [Auteur]
Centre Régional de Lutte contre le Cancer Oscar Lambret [Lille] [UNICANCER/Lille]
Evaluation des technologies de santé et des pratiques médicales - ULR 2694 [METRICS]

Journal title :

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY

Pages :

17588359231192402

Publisher :

SAGE Journals

Publication date :

2023-01

ISSN :

1758-8340

English keyword(s) :

immune checkpoint inhibitor predictive biomarker prognosis biomarker urothelial cancer
immune checkpoint inhibitor
predictive biomarker
prognosis biomarker
urothelial cancer

HAL domain(s) :

Sciences du Vivant [q-bio]/Cancer
Sciences de l'Homme et Société/Méthodes et statistiques
Statistiques [stat]
Statistiques [stat]/Autres [stat.ML]
Statistiques [stat]/Méthodologie [stat.ME]

English abstract : [en]

Immune checkpoint inhibitors (ICIs) are commonly used to treat patients with advanced urothelial cancer. However, a significant number of patients do not respond to ICI, and the lack of validated predictive biomarkers ...
Show more >Immune checkpoint inhibitors (ICIs) are commonly used to treat patients with advanced urothelial cancer. However, a significant number of patients do not respond to ICI, and the lack of validated predictive biomarkers impedes the success of the ICI strategy alone or in combination with chemotherapy or targeted therapies. In addition, some patients experience potentially severe adverse events with limited clinical benefit. Therefore, identifying biomarkers of response to ICI is crucial to guide treatment decisions. The most evaluated biomarkers to date are programmed death ligand 1 expression, microsatellite instability/defective mismatch repair phenotype, and tumor mutational burden. Other emerging biomarkers, such as circulating tumor DNA and microbiota, require evaluation in clinical trials. This review aims to examine these biomarkers for ICI response in urothelial cancer and assess their analytical and clinical validation.Show less >

Language :

Anglais

Peer reviewed article :

Oui

Audience :

Internationale

Popular science :

Non

Collections :

• Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER) - UMR 9020 - UMR 1277

Source :

Harvested from HAL